Capsida Biotherapeutics is a pioneering biotechnology company focused on engineering advanced adenoviral vectors (AAVs) to create novel, targeted gene therapies. With a commitment to addressing debilitating and life-threatening disorders, the company aims to revolutionize treatment methodologies in the life sciences industry.